Europe The European Commission has set itself an ambitious target: making Europe the world’s most attractive destination for life sciences by 2030. In recent conversations with PharmaBoardroom, executives leading Europe for AbbVie, BeOne Medicines, CSL, Merz Therapeutics, and Novartis would love to see this realised and agree that Europe’s scientific fundamentals…
UK Seven months into the job as CEO of GSK, Luke Miels has moved faster and bigger than most expected. Having laid out an M&A strategy based around small bolt-ons at the start of the year, Miels then ripped up his own rule book with the USD 10.6 billion acquisition of…
Global New Takeda CEO Julie Kim inherits a firm with flatlining growth and generic competition eating away at its lead drug’s revenues. Will three major new launches over the next year and swingeing job cuts be enough to revive its fortunes? Now one of just two female Big Pharma CEOs (along…
Germany Our ambition is not simply to bring medicines to market, but to help improve the way dermatology patients are cared for As healthcare systems come under increasing pressure to deliver better outcomes with finite resources, dermatology is evolving beyond medicines alone. Kim Abbenhaus discusses how LEO Pharma is combining scientific…
Germany Transformation often reveals itself not through grand declarations, but through the decisions organisations make about where to invest, what capabilities to build, and how they choose to serve patients. At Angelini Pharma Germany, that evolution is taking shape through a growing commitment to Brain Health, a resilient Consumer Health business,…
USA The US Food and Drug Administration (FDA) finds itself in the midst of unprecedented political turmoil. The Trump Administration’s Department of Government Efficiency (DOGE) removed 3,500 of the Agency’s 20,000 employees in 2025, and a relentless succession of leadership upheavals has compounded the disruption. After 17 months of regulatory and…
Germany With a career spanning senior roles at Galderma, Pierre Fabre Dermo-Cosmétique, Astellas, and Klinge Pharma, Marion Bock brings cross-channel expertise across prescription, consumer, aesthetic, and medical device categories. IBSA Germany has grown from a distributor model to a directly operated affiliate approaching 70 staff and four active commercial business units.…
Taiwan Tina Graves, General Manager of GSK Taiwan, reflects on the affiliate’s strong commercial performance, the strategic shift towards specialty care and oncology, and the urgent case for repositioning adult immunisation as a public health investment. She outlines how Taiwan can become a clinical trial powerhouse, and describes a leadership philosophy…
China In 2024, contract manufacturers WuXi Biologics and WuXi AppTec were catapulted into global consciousness as two of five Chinese service providers deemed a US national security threat in a draft for a new BIOSECURE Act. While the final version of the law, signed by President Donald Trump in December…
Hong Kong As Hong Kong positions itself as a regional healthcare and clinical research hub within the Greater Bay Area, multinational pharma companies are being asked to play a more active role in shaping access to innovation, generating local data, and integrating the territory into global development programmes. Joaquim Antunes Lopes shares…
USA North Carolina has become a focal point for the next phase of biopharmaceutical manufacturing, and FUJIFILM Biotechnologies is placing a significant bet on that momentum. Laurie Braxton discusses how the combination of large-scale capacity, experienced talent, and a tightly integrated site network is shaping a long-term manufacturing platform designed for…
USA Adriana Herrera, CEO of Pierre Fabre Pharmaceuticals Inc, discusses Pierre Fabre’s dedicated expansion into the US market and the unique strategies guiding its next phase of growth. Drawing on more than two decades of leadership experience across global biopharma organizations, Herrera reflects on building a purpose-driven organization, establishing credibility beyond…
See our Cookie Privacy Policy Here
